Please provide your email address to receive an email when new articles are posted on . Cancer screening for high-risk patients with scleroderma should involve basic age, sex and risk factor targeted ...
In a statement, Cabaletta CEO Steven Nichtberger, M.D., highlighted Gavel’s previous experience commercializing cell ...
To the Editor: We believe that an important myositis-associated autoantibody, which could be of interest in the differential diagnosis, was overlooked by Drs. Korn and Mauiyyedi in their discussion of ...
Please provide your email address to receive an email when new articles are posted on . Autoimmune diseases may be easier to treat than cancers using cell therapy. Studies continue to examine its use ...
(MENAFN- GlobeNewsWire - Nasdaq) – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The ...
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback